Journal CME - 2015 June
Back to Journal CME - 2015 June

Journal CME - 2015 June

Summary:

Background: Duration of action increases with repeated administration of neuromuscular-blocking agents, and intraoperative use of high doses of neuromuscular-blocking agent may affect respiratory safety.
Methods: In a hospital-based registry study on 48,499 patients who received intermediate-acting neuromuscular-blocking agents, the authors tested the primary hypothesis that neuromuscular-blocking agents are dose dependently associated with the risk of postoperative respiratory complications. In the secondary analysis, the authors evaluated the association between neostigmine dose given for reversal of neuromuscular-blocking agents and respiratory complications. Post hoc, the authors evaluated the effects of appropriate neostigmine reversal (neostigmine =60 µg/kg after recovery of train-of-four count of 2) on respiratory complications. The authors controlled for patient-, anesthesia-, and surgical complexity–related risk factors.
Results: High doses of neuromuscular-blocking agents were associated with an increased risk of postoperative respiratory complications (n = 644) compared with low doses (n = 205) (odds ratio [OR], 1.28; 95% CI, 1.04 to 1.57). Neostigmine was associated with a dose-dependent increase in the risk of postoperative respiratory complications (OR, 1.51; 95% CI, 1.25 to 1.83). Post hoc analysis revealed that appropriate neostigmine reversal eliminated the dose-dependent association between neuromuscular-blocking agents and respiratory complications (for neuromuscular-blocking agent effects with appropriate reversal: OR, 0.98; 95% CI, 0.63 to 1.52).
Conclusions: The use of neuromuscular-blocking agents was dose dependently associated with increased risk of postoperative respiratory complications. Neostigmine reversal was also associated with a dose-dependent increase in the risk of respiratory complications. However, the exploratory data analysis suggests that the proper use of neostigmine guided by neuromuscular transmission monitoring results can help eliminate postoperative respiratory complications associated with the use of neuromuscular-blocking agents.

CME Credit:

1.00 AMA PRA Category 1 Credit™

Required Hardware / Software:

Adobe Acrobat Reader, Internet connection. Web browser version must have been released within the last three years.

Activity Release Date:
05/19/2015

Activity Expiration Date:
05/18/2018

  • List Price: $20.00 USD
  • Member Price: $0.00 USD

 
Want to save more?
to see if you qualify for a lower rate.
Members save $20.00 USD or more
Item Details:

Learning Objectives:

After successfully completing this activity, the learner will be able to do the following:

- Identify the risks of residual blockade after the administration of an intermediate-acting neuromuscular-blocking agent (NMBA)
- Define the appropriate dose and timing of the...

Back to Journal CME - 2015 June
View More
Back to Product Detail

Thank You Industry Supporters

Whose contributions allow the American Society of Anesthesiologists® to create world-class education and resources to improve patient care and outcomes.

Learn More